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Over the past decades, improved perinatal health care has led to more 
infants that survive preterm birth and consequently a shift in survival to 
earlier gestational ages [1]. However, the chance of event-free survival is 
still low in extremely preterm babies. Nowadays, around 35% of preterm 
infants survive with neurodevelopmental impairments such as cognitive 
defi cits and attention defi cit disorder which rises up to 50-60% in extre-
mely preterm babies (<27 weeks of gestation), and around 10% develop 
motoric spasticity  (CP) [2]. This results in a prevalence of CP around two 
per 1000 live births in developed and in developing countries [3, 4]. As-
suming that in the Netherlands 180.000 children are born annually, this 
accounts for 360 babies born with CP every year. EoP does not only aff ect 
the patient but has an enormous impact on its families and society [5, 6]. 
Substantially increased lifetime costs are therefore attributed to EoP. An-
nually, in the Netherlands the costs for all CP patients comprises € 737,5 
million Euros (0,10 % of BNP) [4]. 
In this thesis, I addressed the time dependent changes in the preterm 
brain in the course of perinatal stress and identifi ed (cell-based, cell-deri-
ved and anti-infective) therapies. For this purpose, we used a translational 
ovine model of preterm brain injury caused by either HI or intrauterine 
infection. The long gestational period of sheep enables us to study ante-
natal developmental processes in detail and to administer our therapies 
at specifi c time-points in during this development. Moreover, ovine brain 
development in utero and the cerebral disease progression following peri-
natal infl ammatory insults (global HI and chorioamnionitis) has essential 
overlap with man [7]. 
The data presented in this thesis (chapter 2-6) support and extend the 
concept that EoP has a multifactorial and complex origin, indicating that 
every newborn child has its own “fi ngerprint” of risk factors potentially 
contributing to EoP development. More precisely, the timing of the pe-
ripheral and cerebral infl ammation and its pathophysiological cerebral 
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changes were shown to be diff erent following a sterile (HI) insult 
when compared to an infectious trigger (chapter 3 & 6). Accor-
dingly, we show that defi ned windows of opportunity emerge fol-
lowing exposure to multiple perinatal infl ammatory triggers. These 
important fi ndings highlight that a potential mismatch might be present 
between the optimal timing of a treatment (in relation to the nature of the 
insult(s)) and the current clinical initiation of a treatment. This mismatch 
impedes development and translation of neurological therapeutics for 
preterm infants. Correct timing of treatment initiation in relation to the 
distinct nature and stage of injury is of great clinical importance in the 
near future. Translation of our fi ndings into the clinical setting demands 
diagnostic tools for the recognition of these perinatal risk factors in a safe 
and non-invasive manner. Our group is currently working on analyzing 
volatile organic compounds in breath condensate of pregnant women to 
determine the presence and/or predict the onset of intra-amniotic infecti-
ons. 
In addition, we performed diff usion MRI sequencing in our study to 
further improve the clinical use of DTI as a biomarker of individual 
neurodevelopment and therapeutic eff ect in the future. Correlation of 
such new crucial imaging biomarkers with microstructural histological 
changes will improve clinical application and subsequently result in an 
individualized treatment approach (chapter 5). Such personalized medi-
cine in which tailor made treatments will be adjusted to individuals need 
is nowadays focus of research in every facet of health care, from preven-
tion to terminal care. The overall aim is to develop new methodologies 
and technological applications that make it easier to predict outcomes in 
individual cases, align treatment with those predictions, and administer 
reliable tests to determine the success of that treatment. Closer coopera-
tion and back-to-back analysis between translational/basic science and 
clinical data will help to achieve this aim. 
Our data (chapter 4) suggests that eradication of Candida Albicans with 
anti-fungal treatment is not suffi  cient to prevent brain injury. Our work 
in chapter 3 supports other reports that describe that cerebral infl amma-
tion that is initiated upon exposure with an infectious trigger continuous 
(postnatally) and might even persist into adulthood. Therefore, future 
treatment protocols should combine multiple therapeutics that harbor 
anti-microbial, immunomodulatory and regenerative capacities to protect 
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against neurodevelopmental disorders in later life. Potential candidates 
that have proven to possess anti-infl ammatory or immunomodulatory ca-
pacities are erythropoietin, cell-based therapies including MSCs/MAPCs 
(chapter 3 & 5) and AnnexinA1 (chapter 6). In chapter 6, we investigate 
the potential therapeutic role of AnxA1 in hypoxic-ischemic encephal-
opathy (HIE). We are the fi rst group to demonstrate a strong potential 
for AnxA1 in the treatment of HI-induced brain injury. The intellectual 
property has been patented which off ers new scientifi c and economic 
opportunities. Future research should focus on route, dose and timing of 
AnxA1 and elucidate whether AnxA1 can act synergistically with other 
therapies including cell-based therapies like MAPCs (Multistem®) that 
have been successfully tested (chapter 5). The potential for MultiStem® to 
treat ischemic stroke is currently being evaluated in a registered trial in 
Japan and in a pivotal Phase 3 clinical trial conducted in North America 
and Europe (clinicaltrial.gov). In addition, this program received the Fast 
Track designation, as well as the Regenerative Medicine Advanced thera-
py designation from the FDA (fda.gov). These designations are designed 
to accelerate the development, regulatory review and subsequent commer-
cialization of product candidates like MultiStem® cell therapy for ische-
mic stroke if the clinical evaluation demonstrates appropriate safety and 
therapeutic eff ectiveness. As a subsequent step, MAPCs can be evaluated 
as therapeutic intervention in neonatal brain injury. In conclusion, the 
fi ndings in this thesis are on short term primary of value to other rese-
archers, but in long term could be translated into commercially available 
products and/or services to improve the outcome of babies at risk for EoP.   
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